Thin
1 / 2
Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy.
Retatrutide is a novel multi-agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed to enhance glucose regulation, promote weight loss, and support metabolic health. It is under active investigation in clinical and preclinical research for obesity and type 2 diabetes management.
Retatrutide is currently an investigational peptide in Phase 3 clinical trials and not yet FDA‑approved for clinical use. Trial protocols have explored once‑weekly subcutaneous doses ranging from 1 mg up to 12 mg, often titrated over multiple 4‑week intervals to balance efficacy and tolerability.
Retatrutide is a novel multi-agonist peptide that acts as a triple receptor agonist, targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors.
It is currently under active investigation for the management of obesity and type 2 diabetes mellitus (T2DM), aiming to enhance glucose regulation and promote weight loss.
No, Retatrutide is currently an investigational peptide in Phase 3 clinical trials and is not yet FDA-approved for clinical use.
In trial protocols, Retatrutide is administered as a once-weekly subcutaneous dose.
Clinical trials have explored doses ranging from 1 mg up to 12 mg.
The dosage is often titrated over multiple 4-week intervals to help balance the drug's efficacy with its tolerability for the patient.
